Novartis Adds Wyeth To Hemophilia Patent Hit List

Law360, New York (October 27, 2008, 12:00 AM EDT) -- Swiss drugmaker Novartis AG has filed an amended complaint against Wyeth Pharmaceuticals Inc. in a patent infringement suit over ReFacto and Xyntha hemophilia treatments.

Novartis' California-based vaccines and diagnostics division, Novartis Vaccines & Diagnostics Inc., filed the amended complaint in the U.S. District for the Eastern District of Texas on Friday, alleging that Wyeth knowingly infringed two patents related to the treatment of the blood-clotting disorder hemophilia.

Novartis originally filed the lawsuit in February 2008.

The patents-at-issue in the lawsuit, U.S. Patent Numbers 6,060,447 and 6,228,620,...
To view the full article, register now.